ExactCure

Certainly! Here is the requested analysis:

ExactCure is a French-based startup founded in 2017, specializing in personalized eHealth software solutions. The company aims to address the issue of inappropriate medical treatments, which result in debilitating side effects, substantial healthcare costs, and even fatalities. The latest milestone for ExactCure was the €1.00M Seed Round investment on 14 November 2019, with OneRagtime being the primary investor.

ExactCure's core offering is the Digital Twin, a revolutionary technology that predicts the concentration and interaction of drugs in the bloodstream based on the patient's unique characteristics. This includes factors such as age, gender, and weight. The solution is designed to be seamlessly integrated into the patient's daily routine as an app, and it also provides a Software as a Service (SaaS) dashboard for healthcare professionals.

The startup's vision is to foster a world where personalized medication is readily available to every individual, while their mission is to anticipate the individualized effects and interactions of drugs within the body. By leveraging this technology, ExactCure aims to enhance and secure medical therapies, ultimately reducing the instances of iatrogenic side effects and the associated healthcare costs.

ExactCure operates within the Biotechnology, Health Care, and Mobile industries, positioning itself at the forefront of innovation in digital health solutions.